

## MEDIA RELEASE - 19 February 2026

### FINANCIAL RESULTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

## Sonic Healthcare delivers solid first half performance and maintains FY 2026 guidance

**Sydney, 19 February 2026 - Sonic Healthcare Limited (ASX: SHL ; ADR: SKHHY)** today reported a solid financial and operational performance for the half-year ended 31 December 2025, underpinned by strong revenue growth, improving earnings per share and disciplined cost control, and maintained full-year FY 2026 guidance.

### Highlights

A\$M	H1 FY 2026	Growth
Revenue	5,445	17%
EBITDA	907	10%
Net profit	262	11%
Cash generated from operations	682	10%
Earnings per share (A\$ cents)	53.1	8%

- On track to achieve full-year EBITDA earnings guidance provided in August 2025 (A\$1.87 to A\$1.95 billion on a constant currency basis).
- Strong revenue growth including organic growth of 5%.
- Operating leverage and synergy realisation demonstrated by EBITDA margin enhancement for the majority of the business.
- Ongoing focus on cost control across the business.
- Operating review of US business underway including rationalisation of anatomical pathology operations.
- Capital management initiatives progressing.
- Progressive dividend policy maintained, increase of 1 cent (2.3%) to 45 cents for the FY 2026 Interim Dividend.

### Commentary

Sonic Healthcare's CEO, Dr Jim Newcombe, said: "Sonic Healthcare's first half result demonstrated the strength and global diversity of the group's operations. We consistently deliver high-value medicine to our global communities and are a trusted partner for doctors, patients and healthcare systems. Our management teams and staff delivered a solid first half result with strong revenue growth, improving earnings per share, and margin expansion in the majority of the business, whilst maintaining a disciplined focus on cost control and capital management. Importantly, we remain on track to achieve our full-year earnings guidance, supported by improving operational performance across most of the Group and the benefits of scale, integration and synergy realisation."

"Sonic's global footprint continues to provide diversification and growth opportunities.

"Our German operations delivered strong organic revenue growth, augmented by the LADR acquisition, with underlying margin improvement, including through disciplined cost control, and synergy capture. Integration of LADR is well advanced, with early synergies already being achieved.

"Our Australia laboratory operations achieved organic growth of 5%, benefiting from partial Medicare indexation, private billing initiatives and continuing strong growth in the specialist and hospital segment. We look forward to commencing pathology services at Australia's largest private hospital, Hollywood Private Hospital in Perth, in the next few weeks.

"Low organic growth and restructuring costs have impacted on margins in the USA, however we have now cycled the loss of the Alabama payor contract and have multiple initiatives underway, with more to come, to drive future revenue growth and enhance profitability. This includes our strategy to expand our advanced diagnostics product offering nationally.

"Our Swiss business is now benefiting from the acquisitions we completed in recent years, with integration well progressed and synergy realisation in line with our plans, driving significant margin expansion. Likewise, the large Herts and West Essex contract in the UK is now profitable, with further margin improvement to come as we optimise the service.

"The radiology division continued its strong organic revenue growth, achieving 7%, albeit somewhat lower than the double-digit growth achieved in the last few years. We continue to focus on the higher value modalities, and to invest in greenfield sites and digital capabilities.

"Sonic Clinical Services achieved 20% earnings growth, benefiting from the acquisition of National Skin Cancer Clinics in April 2025, and a range of cost management initiatives. Additional Medicare funding from November 2025 will assist future revenue and earnings growth.

"Sonic Healthcare enjoys strong market positions and a proven operating model. Our well-established Medical Leadership culture remains a key competitive differentiator, delivering highest quality medical services to patients and doctors globally. We have an ongoing focus on organic revenue growth, efficiency, innovation and disciplined capital management and are confident in our ability to deliver sustainable long-term value for shareholders. I would like to take this opportunity to thank all our staff for the passion, dedication and skill they bring to the company each day for the benefit of our many stakeholders."

**Dr Jim Newcombe**

Chief Executive Officer / Managing Director  
Sonic Healthcare Limited  
Ph: (02) 9855 5333

This announcement has been authorised by the Board of Directors of Sonic Healthcare Limited - please refer to the contact details above.

*For further information regarding the result, please refer to Dr Newcombe's PowerPoint Presentation and to Sonic's H1 FY 2026 Appendix 4D Half Year Report, both of which will be posted on the Sonic Healthcare website by 10:00 am on 19 February 2026 ([www.sonichealthcare.com](http://www.sonichealthcare.com)).*

**Forward-looking statements**

*This media release may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts, or unexpected growth in costs and expenses. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements.*